insights_auto
Kwa nini 688235 imeongezeka kwa 4.06%?
Fahamu zaidichevron_right
688235:SHA
BeOne Medicines AG
CN¥ 255.98
arrow_upward
+4.06%(+9.99) Siku 1
16 Okt, 15:00:00 GMT +8 · CNY
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 688235...
Fungua
CN¥ 253.20
Juu
CN¥ 268.18
Chini
CN¥ 252.09
Mtaji wa soko
303.26B
Wastani wa kiasi cha mauzo
2.81M
Kiasi cha mauzo ya hisa
5.69M
Uwiano wa bei ya hisa na mapato kwa kila hisa
91.43
Juu kwa wiki 52
CN¥ 319.24
Chini kwa wiki 52
CN¥ 205.51
EPS
CN¥ 2.80
Idadi ya wafanyakazi
elfu 12
Fungua
CN¥ 253.20
Juu
CN¥ 268.18
Chini
CN¥ 252.09
Mtaji wa soko
303.26B
Wastani wa kiasi cha mauzo
2.81M
Kiasi cha mauzo ya hisa
5.69M
Uwiano wa bei ya hisa na mapato kwa kila hisa
91.43
Juu kwa wiki 52
CN¥ 319.24
Chini kwa wiki 52
CN¥ 205.51
EPS
CN¥ 2.80
Idadi ya wafanyakazi
elfu 12
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 22 zilizopita
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Wasifu
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Kuhusu BeOne Medicines AG
Afisa Mkuu Mtendaji (CEO)John Vincent Oyler | John Vincent Oyler
Wafanyakazielfu 12
Lilianzishwa28 Okt 2010
Makao makuu-
Sekta-
Tovutibeonemedicines.com